The industry’s leading scalable electroporation technology for high yield transient expression of complex proteins, vaccines and biologics.

  • Rapidly transfect from 75 thousand to 20 billion cells
  • High efficiency with flexible media strategies deliver significant cost savings
  • Improved yields, at scale, can decrease development timelines
  • Proprietary Flow Electroporation™ Technology
  • Faster production of stable clones
  • ISO-certified, and CE-marked

Resources3D VIEWQuote

Download STx